AU2018234056B2 - Subcutaneous administration of a P2Y12 receptor antagonist - Google Patents

Subcutaneous administration of a P2Y12 receptor antagonist Download PDF

Info

Publication number
AU2018234056B2
AU2018234056B2 AU2018234056A AU2018234056A AU2018234056B2 AU 2018234056 B2 AU2018234056 B2 AU 2018234056B2 AU 2018234056 A AU2018234056 A AU 2018234056A AU 2018234056 A AU2018234056 A AU 2018234056A AU 2018234056 B2 AU2018234056 B2 AU 2018234056B2
Authority
AU
Australia
Prior art keywords
receptor antagonist
administered
pharmaceutically acceptable
acceptable salt
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018234056A
Other languages
English (en)
Other versions
AU2018234056A1 (en
Inventor
Martine BAUMANN
Markus KRAMBERG
Markus REY
Markus Riederer
Sebastien Roux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viatris Asia Pacific Pte Ltd
Original Assignee
Viatris Asia Pacific Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Asia Pacific Pte Ltd filed Critical Viatris Asia Pacific Pte Ltd
Publication of AU2018234056A1 publication Critical patent/AU2018234056A1/en
Application granted granted Critical
Publication of AU2018234056B2 publication Critical patent/AU2018234056B2/en
Assigned to VIATRIS ASIA PACIFIC PTE. LTD. reassignment VIATRIS ASIA PACIFIC PTE. LTD. Request for Assignment Assignors: IDORSIA PHARMACEUTICALS LTD
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018234056A 2017-03-15 2018-03-14 Subcutaneous administration of a P2Y12 receptor antagonist Active AU2018234056B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/056175 2017-03-15
EP2017056175 2017-03-15
PCT/EP2018/056372 WO2018167139A1 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a p2y12 receptor antagonist

Publications (2)

Publication Number Publication Date
AU2018234056A1 AU2018234056A1 (en) 2019-10-31
AU2018234056B2 true AU2018234056B2 (en) 2023-05-25

Family

ID=61899166

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018234056A Active AU2018234056B2 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a P2Y12 receptor antagonist

Country Status (19)

Country Link
US (1) US11179390B2 (enExample)
EP (1) EP3595666A1 (enExample)
JP (3) JP7580918B2 (enExample)
KR (1) KR102510832B1 (enExample)
CN (1) CN110381947A (enExample)
AU (1) AU2018234056B2 (enExample)
BR (1) BR112019014567A2 (enExample)
CA (1) CA3050831A1 (enExample)
CL (1) CL2019002318A1 (enExample)
EA (1) EA201992123A1 (enExample)
IL (1) IL269286B2 (enExample)
MA (1) MA49887A (enExample)
MX (1) MX393334B (enExample)
MY (1) MY205605A (enExample)
PH (1) PH12019502111A1 (enExample)
SG (1) SG11201908128YA (enExample)
TW (1) TWI765002B (enExample)
UA (1) UA125531C2 (enExample)
WO (1) WO2018167139A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752086B (zh) 2016-09-22 2022-01-11 瑞士商愛杜西亞製藥有限公司 結晶型式
CA3185564A1 (en) 2020-07-15 2022-01-20 Stephan Buchmann Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
JP2024524658A (ja) 2021-07-13 2024-07-05 イドルシア・ファーマシューティカルズ・リミテッド ４－（（ｒ）－２－｛［６－（（ｓ）－３－メトキシ－ピロリジン－１－イル）－２－フェニル－ピリミジン－４－カルボニル］－アミノ｝－３－ホスホノ－プロピオニル）－ピペラジン－１－カルボン酸ブチルエステルの合成方法
US20250197904A1 (en) 2022-03-14 2025-06-19 Viatris Asia Pacific Pte. Ltd. A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
EP1192132B1 (en) 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
US7056923B2 (en) 2002-12-11 2006-06-06 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
DK1611144T3 (da) 2003-04-09 2010-11-22 Wyeth Llc Derivater af 2-(8,9-dioxo-2,6-diazabicyclo(5.2.0)non-1(7)-en-2-yl)alkyl-phosphonsyre og deres avendelse som n-methyl-D-aspartat (NMDA)-receptor-antagonister
WO2005002574A1 (en) 2003-06-24 2005-01-13 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
MY147373A (en) 2005-10-21 2012-11-30 Actelion Pharmaceuticals Ltd Piperazine derivatives as antimalarial agents
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
WO2008128647A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
MX2009011843A (es) 2007-05-02 2010-04-22 Portola Pharm Inc Dosificacion intravenosa y oral de un inhibidor de p2y12 de accion directa y reversible.
HRP20120735T1 (hr) 2007-11-29 2012-10-31 Actelion Pharmaceuticals Ltd. Derivati fosfonske kiseline i njihova uporaba kao antagonista p2y12 receptora
WO2009080227A2 (en) 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
EP2238128B1 (en) 2007-12-26 2012-08-22 Sanofi Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
NZ596213A (en) 2009-04-08 2013-05-31 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adenosine 5'-diphosphate (ADP) receptor antagonists
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
WO2011160768A1 (en) 2010-06-23 2011-12-29 Stefan Kralev Medical device for self-administration of patients with acute coronary events
TWI752086B (zh) 2016-09-22 2022-01-11 瑞士商愛杜西亞製藥有限公司 結晶型式

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. Baldoni, et al.; "A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial", Clin. Drug Investig. 2014, 34(11): 807-818. *
E. Caroff, et al.; "4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug", J. Med. Chem. 2015, 58(23): 9133-9153. *

Also Published As

Publication number Publication date
US20200129510A1 (en) 2020-04-30
CN110381947A (zh) 2019-10-25
SG11201908128YA (en) 2019-10-30
BR112019014567A2 (pt) 2020-02-18
EP3595666A1 (en) 2020-01-22
IL269286B2 (en) 2023-08-01
EA201992123A1 (ru) 2020-02-25
NZ757938A (en) 2024-07-05
PH12019502111A1 (en) 2020-03-16
JP2020510043A (ja) 2020-04-02
JP2023052576A (ja) 2023-04-11
KR102510832B1 (ko) 2023-03-15
WO2018167139A1 (en) 2018-09-20
IL269286B1 (en) 2023-04-01
US11179390B2 (en) 2021-11-23
JP7580918B2 (ja) 2024-11-12
UA125531C2 (uk) 2022-04-13
KR20190124297A (ko) 2019-11-04
CA3050831A1 (en) 2018-09-20
TW201840323A (zh) 2018-11-16
AU2018234056A1 (en) 2019-10-31
MX393334B (es) 2025-03-24
MA49887A (fr) 2020-06-24
IL269286A (en) 2019-11-28
TWI765002B (zh) 2022-05-21
CL2019002318A1 (es) 2020-01-10
MX2019009559A (es) 2019-10-15
MY205605A (en) 2024-10-29
JP2025060907A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
JP2025060907A (ja) Ｐ２ｙ１２受容体アンタゴニストの皮下投与
US20220125753A1 (en) Compositions and methods for treating ischemic stroke
JP7664862B2 (ja) ニコランジル誘導体
KR20180032578A (ko) 염증 및 암 질환의 치료를 위한 클로로퀸 및 클레미졸 화합물의 용도
KR20140022052A (ko) 심근 경색 후 환자에서의 심부전 및 부정맥 치료를 위한 ａ２ｂ 아데노신 수용체 안타고니스트의 용도
EP4592294A1 (en) Novel carbamate compound and use thereof
EP4181872B1 (en) Aqueous pharmaceutical composition comprising a p2y12 receptor antagonist
JP2023082167A (ja) 薬物動態及び／又は安全性に優れるテリパラチド含有液状医薬組成物
US9308174B2 (en) Lyophilized formulations of bendamustine hydrochloride
CN104321323A (zh) 碳环核苷及其医药用途和组合物
EA042138B1 (ru) Подкожное введение антагониста p2y12 рецептора
TWI905227B (zh) 包含p2y12受體拮抗劑的水性醫藥組合物
Thakur¹ et al. Review on chemistry and pharmacology of dabigatran a potent anticoagulant
Nugroho et al. Population Pharmacokinetics Modeling of Levofloxacin In Rabbit By Intravenous Bolus Injection and Peroral Administration

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: VIATRIS ASIA PACIFIC PTE. LTD.

Free format text: FORMER OWNER(S): IDORSIA PHARMACEUTICALS LTD